Clinical-stage biotechnology company Neogap Therapeutics has partnered with NorthX Biologics to advance manufacturing strategies for its personalised cancer cell therapy.

This collaboration, funded by the European Innovation Council (EIC) Accelerator, focuses on optimising and scaling production for upcoming clinical trials. Neogap's cell therapy, pTTL, trains the immune system to recognize and attack cancer cells using patient-specific neoantigens and is currently in Phase I/II trials for advanced colorectal cancer. The partnership aims to build a cost-effective, scalable production framework to support larger clinical trials and future commercialization.

Key initiatives include enhancing manufacturing protocols, scaling out production processes and ensuring GMP compliance. Streamlined logistics and production processes are expected to improve efficiency, resilience, and cost-effectiveness.

Neogap's collaboration with NorthX Biologics reflects a strategic step toward expanding clinical applications and increasing patient access.